686 related articles for article (PubMed ID: 33169187)
1. Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed.
Meemanage M; Spender LC; Collinson D; Iannetta J; Challapalli P; Turbitt J; Clark C; Baxter M; Murray G; Walsh S; Miedzybrodzka Z; Petty RD
Cancer Chemother Pharmacol; 2021 Mar; 87(3):361-377. PubMed ID: 33169187
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
4. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Morelli MP; Cascone T; Troiani T; De Vita F; Orditura M; Laus G; Eckhardt SG; Pepe S; Tortora G; Ciardiello F
Ann Oncol; 2005 May; 16 Suppl 4():iv61-68. PubMed ID: 15923432
[TBL] [Abstract][Full Text] [Related]
5. Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Pelosof L; Saung MT; Donoghue M; Casak S; Mushti S; Cheng J; Jiang X; Liu J; Zhao H; Khazraee M; Goldberg KB; Theoret M; Lemery S; Pazdur R; Fashoyin-Aje L
Oncologist; 2021 Apr; 26(4):318-324. PubMed ID: 33345396
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Petty RD; Dahle-Smith A; Stevenson DAJ; Osborne A; Massie D; Clark C; Murray GI; Dutton SJ; Roberts C; Chong IY; Mansoor W; Thompson J; Harrison M; Chatterjee A; Falk SJ; Elyan S; Garcia-Alonso A; Fyfe DW; Wadsley J; Chau I; Ferry DR; Miedzybrodzka Z
J Clin Oncol; 2017 Jul; 35(20):2279-2287. PubMed ID: 28537764
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review.
Xu J; Bai Y; Li E; Xu N; Shi D; Qian J
Expert Rev Anticancer Ther; 2022 Sep; 22(9):981-998. PubMed ID: 35950848
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Huang J; Xu B; Liu Y; Huang J; Lu P; Ba Y; Wu L; Bai Y; Zhang S; Feng J; Cheng Y; Li J; Wen L; Yuan X; Ma C; Hu C; Fan Q; Wang X
Cancer Commun (Lond); 2019 Apr; 39(1):16. PubMed ID: 30940189
[TBL] [Abstract][Full Text] [Related]
11. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Abraham P; Gricar J; Zhang Y; Shankaran V
Adv Ther; 2020 Jul; 37(7):3392-3403. PubMed ID: 32533533
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
14. Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma.
Yang LY; Cheng ZJ; Liu Z; Wang D; Zhang N; Fan ZL; Cai HQ; Zhang Y; Cai Y; Xu X; Wang JH; Du GH; Hao JJ; Wang MR
J Gastroenterol Hepatol; 2021 Sep; 36(9):2513-2522. PubMed ID: 33721913
[TBL] [Abstract][Full Text] [Related]
15. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Lin J; Wu H; Shi H; Pan W; Yu H; Zhu J
PLoS One; 2013; 8(10):e76169. PubMed ID: 24155892
[TBL] [Abstract][Full Text] [Related]
17. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201.
Yamamoto S; Kawakami H; Kii T; Hara H; Kawabata R; Kawada J; Takeno A; Matsuyama J; Ueda S; Okita Y; Endo S; Kimura Y; Yanagihara K; Okuno T; Kurokawa Y; Shimokawa T; Satoh T
Eur J Cancer; 2021 Sep; 154():307-315. PubMed ID: 34311300
[TBL] [Abstract][Full Text] [Related]
20. Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Tsai CM; Chen JT; Stewart DJ; Chiu CH; Lai CL; Hsiao SY; Chen YM; Chang KT
J Thorac Oncol; 2011 Mar; 6(3):559-68. PubMed ID: 21258258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
